These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 33330629)

  • 1. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
    Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
    Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
    He Z; Feng W; Wang Y; Shi L; Gong Y; Shi Y; Shen S; Huang H
    Transl Lung Cancer Res; 2023 Mar; 12(3):510-529. PubMed ID: 37057124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
    Wang Z; Wang C; Lin S; Yu X
    Front Oncol; 2021; 11():725292. PubMed ID: 34513703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.
    Liu M; Yang M; Zhang B; Xia S; Zhao J; Yan L; Ren Y; Guo H; Zhao J
    J Mol Med (Berl); 2024 Jul; 102(7):899-912. PubMed ID: 38739269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors.
    Wen Y; Lin A; Zhu W; Wei T; Luo P; Guo L; Zhang J
    Front Pharmacol; 2021; 12():645862. PubMed ID: 34163353
    [No Abstract]   [Full Text] [Related]  

  • 8. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
    Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
    BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis¬†of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
    Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
    Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
    Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
    BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis.
    Lin A; Fang J; Cheng Q; Liu Z; Luo P; Zhang J
    J Inflamm Res; 2022; 15():5541-5555. PubMed ID: 36176353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
    Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
    Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Li Y; Yang Q; Liu Y; Yi H; Ju Y; Qi G
    Invest New Drugs; 2023 Aug; 41(4):556-563. PubMed ID: 37318657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Su S; Lin A; Luo P; Zou J; Huang Z; Wang X; Zeng Y; Cen W; Zhang X; Huang H; Hu J; Zhang J
    Ann Transl Med; 2021 Sep; 9(18):1475. PubMed ID: 34734027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
    Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
    Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
    Sun L; Li M; Deng L; Niu Y; Tang Y; Wang Y; Guo L
    Front Pharmacol; 2021; 12():625593. PubMed ID: 33927616
    [No Abstract]   [Full Text] [Related]  

  • 20. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
    Chen Z; Chen J; Ren D; Zhang J; Yang Y; Zhang H; Mao B; Ma H
    Aging (Albany NY); 2020 Dec; 13(1):598-618. PubMed ID: 33288738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.